What's Happening?
Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The event will take place from September 8-10, 2025, at the Lotte New York Palace Hotel. Jeffrey Frelick, the company's President and CEO, will represent Bone Biologics, engaging in both in-person and virtual meetings with institutional investors and industry professionals. The conference provides a platform for the company to showcase its advancements in regenerative medicine, particularly its work on the NELL-1 protein for bone regeneration in spinal fusion procedures.
Why It's Important?
Participation in the H.C. Wainwright Global Investment Conference is a strategic opportunity for Bone Biologics to attract potential investors and partners. The company's focus on regenerative medicine and orthobiologic products positions it at the forefront of innovation in the healthcare sector. By engaging with industry leaders and investors, Bone Biologics aims to secure funding and partnerships that could accelerate the development and commercialization of its products. This engagement is crucial for the company's growth and its ability to bring advanced medical solutions to market, potentially improving outcomes for patients undergoing spinal fusion surgeries.
